The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste-Reference-Cited by-同舟云学术

The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste

Published:2023-02 Issue:2 Volume:7 Page:100074
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Donners Anouk A.M.T.^ORCID,van der Zwet Konrad^ORCID,Rademaker Carin M.A.^ORCID,Egberts Toine C.G.^ORCID,Schutgens Roger E.G.^ORCID,Fischer Kathelijn^ORCID

Publisher

Elsevier BV

Subject

Hematology

Reference22 articles.

1. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies;Callaghan;Blood,2021

2. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors;Jimenez-Yuste;Haemophilia,2021

3. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors;Cafuir;J Med Econ,2022

4. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe;Mancuso;J Med Econ,2022

5. Health Institute Netherlands. Horizonscan Geneesmiddelen: emicizumab (Hemlibra). Version 6; 2020. www.horizonscangeneesmiddelen.nl/geneesmiddelen/emicizumab-cardiovasculaire-aandoeningen-hemostase_bevorderende_medicatie/versie6, [accessed November 15, 2022].

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validación de un método para la cuantificación plasmática de emicizumab;Revista Hematología;2024-01-22

2. Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective;Saudi Pharmaceutical Journal;2023-12

3. Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres;Haemophilia;2023-08-30

4. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A;BMJ Open;2023-06

5. The dosing conundrum of emicizumab: To waste product or not?;Research and Practice in Thrombosis and Haemostasis;2023-02